Aurobindo Pharma’s arm recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths

16 Dec 2024 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc., is recalling over 1 lakh bottles of Cinacalcet tablets in multiple strengths in the US market. The New Jersey-based firm is recalling the product due to 'GMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limit. The company initiated the Class II recall on November 7, 2024. Cinacalcet tablets are used to treat hyperparathyroidism. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1247.85 34.40 (2.83%)
18-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.30
Dr. Reddys Lab 1275.05
Cipla 1472.05
Lupin 2098.70
Zydus Lifesciences 979.10
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.